Sandoz Delivers Denosumab Data As Biogen Sues On Tysabri

Company Eyeing 2024 Denosumab Launch; Natalizumab Accepted In US, EU

 
• By Dean Rudge
  
race car
Sandoz is said to be leading the race on denosumab • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products